Gary Raskob to United States
This is a "connection" page, showing publications Gary Raskob has written about United States.
Connection Strength
0.854
-
Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
Score: 0.134
-
Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
Score: 0.116
-
The Value of Prevention Research Centers: Breaking New Ground in Prevention Research. Am J Prev Med. 2017 03; 52(3 Suppl 3):S214-S215.
Score: 0.092
-
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10.
Score: 0.084
-
The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18.
Score: 0.082
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
Score: 0.058
-
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9.
Score: 0.057
-
Injury prevention and control research and training in accredited schools of public health: a CDC/ASPH assessment. Public Health Rep. 2006 May-Jun; 121(3):349-51.
Score: 0.043
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
Score: 0.024
-
Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5.
Score: 0.022
-
The US Cancer Moonshot initiative. Lancet Oncol. 2016 05; 17(5):e178-80.
Score: 0.022
-
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
Score: 0.021
-
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
Score: 0.015
-
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37.
Score: 0.014
-
Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30.
Score: 0.013
-
Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31.
Score: 0.013
-
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81.
Score: 0.011
-
Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
Score: 0.008
-
Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
Score: 0.007
-
Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12.
Score: 0.006
-
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
Score: 0.006
-
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
Score: 0.006